Skip to Main Content

The Editas Medicine Mission

Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.

What We’re Working On

We’re using CRISPR, a powerful genome editing technology to develop new gene edited medicines. We are researching and developing both in vivo gene edited medicines, which edit genes inside the body, and ex vivo gene edited cell medicines, where editing occurs in cells outside the body and those edited cells are transferred into patients.

Dive into our work

Download

Gene editing has the potential to change outcomes within a broad range of diseases. Right now, we’re concentrating our efforts on three major therapeutic areas.

Ocular diseases

Leber Congenital Amaurosis 10 (LCA10), Usher syndrome 2A (USH2A), retinitis pigmentosa (RP4)

Blood diseases

Sickle cell disease (SCD), Beta-thalassemia

Oncology

Developing both autologous and allogeneic ex vivo gene edited cell medicines for the treatment of solid tumors and blood cancers


Executive Leadership

  • James (Jim) C. Mullen,

    Chairman, President, and Chief Executive Officer

  • James (Jim) Mullen joined the Editas Medicine Board of Directors as Chairman in March 2018 and in February 2021 was appointed as President and CEO.

    Jim is a recognized biotech leader with more than 40 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, he served as Chief Executive Officer of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher), in August 2017. Before joining Patheon, Jim served as Chief Executive Officer and President at Biogen, Inc. (Biogen), one of the world’s largest biotechnology companies. Prior to being named Chief Executive Officer, he held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations.

    Jim also serves on the Board of Directors of Thermo Fisher Scientific. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer, Inc. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization.

    Jim holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

  • Bruce E. Eaton, Ph.D.,

    Executive Vice President and Chief Business Officer

  • Bruce is Executive Vice President and Chief Business Officer of Editas Medicine. At Editas, Bruce oversees the Company’s business development, alliance management, and strategy initiatives.

    Bruce has more than 30 years of biotech scientific, operations, business development, and corporate strategy experience in both public and private companies. He has a deep understanding of biotechnology for the innovation and development of medicines. Throughout his career, Bruce has founded multiple companies in both life sciences and human therapeutics and has served in C-level and director level roles. In addition, he has acted as an advisor to numerous government and academic research institutions. He also serves on the Board of Directors of the Colorado Bioscience Association.

    Bruce began consulting as a senior advisor to Editas in 2015 and continued his working relationship with Editas through a research collaboration beginning in 2016. Bruce joined Editas as the Boulder Site Head in January 2018 with the acquisition of assets from i2 Pharmaceuticals where he was Founder and CEO. Prior to i2, Bruce was Chief Operating Officer of SomaLogic, where he was responsible for operations, business development, and corporate strategy. Earlier in his career, Bruce served as Vice President of NexaGen and was on the integration team responsible for the merger with Vestar and the formation of NexStar Pharmaceuticals where he built and led the groups responsible for good manufacturing practice (GMP) synthesis and analytics for an investigational new drug (IND) application for the Age-Related Macular Degeneration (AMD) drug Macugen™ (Bausch + Laumb). At NexStar, Bruce was also responsible for alliance management of all research and process development efforts to support the liposomal delivery technology of the drug Ambisome™ (Gilead Sciences, Inc., and Astellas Pharma, Inc.).

    Bruce received his Ph.D. in chemistry from the University of California at Berkeley. He earned B.S. degrees in biology and in chemistry from the University of Oregon, and he has received numerious academic awards throughout his career.

  • Harry Gill,

    Senior Vice President, Operations

  • Harry is Senior Vice President, Operations of Editas Medicine. He joined Editas Medicine in September 2019 as interim Head of Operations and was named Senior Vice President, Operations in January 2020.

    Harry brings more than 30 years of life sciences experience to this role. Throughout his career, Harry has held leadership roles in quality, plant operations, technical services, and operational excellence.

    Harry served as Senior Vice President of Quality and Continuous Improvement at Patheon pharmaceuticals (now ThermoFisher Scientific). Earlier in his career, Harry held various positions at Wyeth (now Pfizer Pharmaceuticals) and Baxter Healthcare Corporation. In addition, he has eight years of international experience, holding manufacturing operations positions in Asia and Puerto Rico.

    Harry received a BS degree in biology from Milligan College and a MS in microbiology from East Tennessee State University.

  • Chi Li, Ph.D., MBA, RAC

    Senior Vice President and Chief Regulatory Officer

  • Chi is Senior Vice President and Chief Regulatory Officer of Editas Medicine. He joined Editas Medicine in June 2021 and is responsible for leading Editas Medicine’s regulatory affairs strategy and activities related to its drug development programs.

    Chi brings to Editas more than 20 years of experience in drug development in the pharmaceutical and biotechnology industry. He played an important and strategic role in the development, submission, and approval of several drugs and biologics across a number of therapeutic areas, globally and in the United States. Before joining Editas, Chi served as Chief Regulatory Officer at Celularity, and as Vice President, Regulatory Affairs at both Allergan and Bayer.

    Chi earned a Ph.D. in organic chemistry from Purdue University and an MBA from Rutgers University. He holds a Regulatory Affairs Certification from the Regulatory Affairs Professionals Society.

  • Lisa A. Michaels, M.D.,

    Executive Vice President and Chief Medical Officer

  • Lisa is Executive Vice President and Chief Medical Officer of Editas Medicine. She joined Editas Medicine in November 2020 and is responsible for leading the development activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic indications including, ophthalmology, oncology, hematology, and immunologic diseases.

    Lisa brings to Editas more than 25 years of experience in clinical research and drug development in both industry and academia. Lisa joined Editas Medicine from Bayer Pharmaceuticals where she spent more than 10 years in drug development, leading teams from early research and drug discovery through regulatory approval, commercial launch, and life cycle management. Most recently, she served as head of Bayer’s Rare Diseases, Cell & Gene Therapy therapeutic area.

    Earlier in her career, Lisa spent more than 15 years at the Robert Wood Johnson Medical School at Rutgers University in academic practice working in areas including benign and malignant hematology, solid tumors, bone marrow failure syndromes, thrombosis and hemostasis, and immunologic disorders, including cytopenias and immune deficiencies.

    Lisa received her M.D. at the University of Virginia, Charlottesville during which she received additional training in translational research in autoimmune disease, immune deficiencies, and disorders of complement, at the National Institute for Allergy and Infectious Disease in Washington, DC, and completed a preceptorship in pediatric cardiovascular care at Mayo Clinic, in Rochester, Minnesota. Lisa completed her residency and qualification in pediatrics at Duke University and post-graduate fellowship and qualification in hematology and oncology at the Children’s Hospital of Philadelphia.

  • Michelle Robertson,

    Chief Financial Officer

  • Michelle is Chief Financial Officer of Editas Medicine. She joined Editas Medicine in January 2020 and oversees the finance, investor relations, and information technology teams and activities.

    Prior to joining Editas Medicine, Michelle served as Chief Financial Officer of Momenta Pharmaceuticals, Inc. She joined Momenta as Vice President, Financial Planning and Analysis. Prior to joining Momenta, Michelle was Vice President, Oncology Finance for Baxalta, Inc. (which was acquired by Shire PLC in 2016) following its spin-out from Baxter International in July 2015. Before that, Michelle served as head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, and, prior to that, she held various leadership positions in the Oncology and Biosurgery divisions with Finance and Commercial Operations, focusing on financial analysis for business development, acquisition integrations, and divestitures at Genzyme Corporation.

    Michelle received her BS in Finance from Bentley University. Michelle also serves on the Board of Directors for Verastem Oncology.

  • Mark S. Shearman, Ph.D.

    Executive Vice President and Chief Scientific Officer

  • Mark is Executive Vice President and Chief Scientific Officer of Editas Medicine. He joined Editas Medicine in June 2021 and is responsible for leading the drug discovery and development activities related to Editas Medicine’s pipeline of experimental medicines across all indications.

    Mark brings to Editas more than 30 years of experience in drug discovery and development across multiple therapeutic modalities. Mark joins Editas Medicine from Applied Genetic Technologies Corporation (AGTC), where he served as Chief Scientific Officer and was responsible for leading the company’s product candidate selection process, pre-clinical and translational research, and long-term research and development planning. Prior to AGTC, Mark served as Senior Vice President of Research & Early Development at EMD Serono, Inc., the U.S. and Canadian subsidiary of Merck KGaA. Previously, Mark was Executive Director of Merck & Co. Research Laboratories, Boston, and Senior Director at the Merck Sharp & Dohme Research Laboratories Neuroscience Research Centre in the United Kingdom.

    Prior to his career in Industry, Mark pursued academic science, having been awarded post-doctoral fellowships with Yasutomi Nishizuka (Kobe Medical School, Japan) and Axel Ullrich (Max Planck Institute, Munich, Germany).

    Mark has co-authored more than 130 research publications (Nature, Cell, PNAS, EMBO J, JBC, Human Gene Therapy); has been an invited speaker at more than 65 national and international meetings; and served on numerous editorial, grant review, scientific advisory boards and expert advisory panels.

    Mark earned a B.Sc. from the University of Bristol, U.K., and a Ph.D. from the University of Nottingham, U.K.

  • Charlene Stern, Ph.D., J.D.,

    Senior Vice President and Chief Legal Officer

  • A headshot of Charlene Stern.
  • Charlene was part of the team that launched Editas Medicine in 2013. As Chief Legal Officer, she oversees and manages all legal matters, including corporate governance, securities compliance and SEC reporting, partnering and licensing transactions, financings, and intellectual property strategy. She also serves as Editas Medicine’s Corporate Secretary. Prior to Editas Medicine, Charlene was senior patent counsel at AVEO Oncology, where she was responsible for developing and executing AVEO’s intellectual property strategy. Earlier in her career, she was a senior attorney in the Boston office of Goodwin LLP and a patent agent at Foley Hoag LLP. Before beginning her legal career, Charlene was an American Cancer Society post-doctoral fellow at Dana-Farber Cancer Institute. She received her J.D. from Suffolk University Law School, a Ph.D. in cell and molecular biology from Yale University, and an A.B. in biochemistry from Mount Holyoke College.

Board of Directors

James (Jim) Mullen joined the Editas Medicine Board of Directors as Chairman in March 2018 and in February 2021 was appointed as President and CEO.

Jim is a recognized biotech leader with more than 40 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, he served as Chief Executive Officer of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher), in August 2017. Before joining Patheon, Jim served as Chief Executive Officer and President at Biogen, Inc. (Biogen), one of the world’s largest biotechnology companies. Prior to being named Chief Executive Officer, he held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations.

Jim also serves on the Board of Directors of Thermo Fisher Scientific. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer, Inc. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization.

Jim holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

Dr. Meeta Chatterjee joined the Editas Medicine Board of Directors in December 2020. Meeta is an accomplished biopharmaceutical executive with more than 30 years of broad strategic and operational experience in research and development, mergers and acquisition evaluation, in-licensing, and externalization activities.

Meeta currently serves as Senior Vice President of Global Business Development at Legend Biotech where she provides oversight for all business development activities including prioritizing opportunities, managing evaluations, and executing transactions. Meeta also leads Alliance Management activities at Legend. In addition to her responsibilities at Legend, Meeta serves on the Board of Directors at Werewolf Therapeutics, Inc.

Prior to joining Legend Biotech, Meeta was Head of Strategy, Transactions, and Operations in the Business Development and Licensing (BD&L) group at Merck Research Labs. In that role, Meeta oversaw all discovery and late stage transactions worldwide and early-stage transactions in key geographies. She was also responsible for Merck Research Labs BD&L governance as well as out-licensing efforts.

Over the course of her extensive career, she has led or contributed to numerous successful transactions and collaborations that had significant strategic and financial impact on the overall business. In her roles within research, she led programs in the areas of hypertension, atherosclerosis, and obesity, including programs leading to the discovery of ZETIA® and ZONTIVITY®.

Meeta holds a B.A. in Physics from St. Xavier’s University in Ahmedabad, India, and Rutgers University, and a Ph.D. in Physiology from Rutgers University. She completed her post-doctoral fellowship in the Department of Physiology at the University of Virginia School of Medicine.

Bernadette Connaughton joined the Editas Medicine Board of Directors in October 2021. Bernadette is an accomplished pharmaceutical executive with more than 30 years of global strategic, commercial, and biopharmaceutical industry expertise.

Bernadette spent her career at Bristol-Myers Squibb, building a consistent track record of achieving sales growth, improving operational models, and increasing profitability in the U.S., European, and Asian markets. She most recently served as President, Intercontinental. In this role, she developed successful, multi-year commercialization strategies for several oncology, virology, and immunology products.

Bernadette currently serves on the Board of Directors of Syneos Health, Inc., Zealand Pharma A/S, and Halozyme Therapeutics, Inc. She also serves on the Board of Trustees of the Boys and Girls Club of Mercer County, New Jersey. She was previously a member of the Board of Directors of Visterra, Inc.

Bernadette received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania.

Andrew joined the Editas Medicine Board of Directors in May 2017 with more than 20 years of experience in a range of strategic and operating business roles, including more than 15 years in the biotech industry. Andrew currently serves as President, Chief Executive Officer and a member of the Board of Directors of C4 Therapeutics (C4T). Prior to C4T, Andrew served as Chief Financial Officer at Agios Pharmaceuticals, Inc., and as its Head of Corporate Development. Earlier in his career, Andrew served as President and Chief Executive Officer of BIND Therapeutics, Inc., and as Chief Financial Officer at Avila Therapeutics, Inc., until its acquisition by Celgene Corporation. He also held roles of increasing responsibility during his nearly 10-year tenure at Biogen, including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team.

Andrew holds an MBA from the Tuck School at Dartmouth College and a BA in Economics from the University of Pennsylvania.

Jessica is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She joined the Editas Medicine Board of Directors in February 2018. Jessica serves as an Independent Director on the Board of Directors of Insulet Corporation and Maravai LifeSciences, Inc., and she is a Trustee of the Joslin Diabetes Center. In addition, she is a strategic advisor to and investor in start-up healthcare firms.

Jessica is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice, where she led work in strategy, R&D management, and marketing across pharmaceutical, biotech, medical-device, and consumer industries. She also held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing.

Jessica earned a BS from Yale College, an MBA from Harvard Graduate School of Business Administration as a Baker Scholar, and a Ph.D. in neuroscience/biochemistry from the Rockefeller University.

Emma Reeve joined the Editas Medicine Board of Directors in September 2021. Emma is an accomplished biopharmaceutical executive with more than 25 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies.

Most recently, Emma served as Chief Financial Officer of Constellation Pharmaceuticals, Inc., a development-stage oncology company, prior to its acquisition by MorphoSys AG in 2021. Emma led Constellation’s IPO in 2018.

Prior to Constellation, Emma acted as interim Chief Financial Officer and Corporate Controller of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement, and facilities. In this role, she led the finance aspects of a sell-side process which culminated in an agreement to take the company private in a $5 billion leveraged buy-out.

Earlier in her career, Emma served as Chief Financial Officer of both Inotek Pharmaceuticals and Aton Pharma. Additionally, she held senior finance and operational roles at Bristol-Myers Squibb, Merck, and Novartis.

Emma holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.

David joined the Editas Medicine Board of Directors in February 2019. He is a hematologist/oncologist and an expert in stem-cell biology and blood malignancies. He is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He founded and directs the Center for Regenerative Medicine at Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute. He is chairman emeritus and Professor of the Harvard University Department of Stem Cell and Regenerative Biology. David has published more than 350 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem-cell function.

David is the recipient of numerous honors, including elected membership of the National Academy of Medicine and the American Academy of Arts and Sciences, a fellowship at the American College of Physicians and at the American Association for the Advancement of Science, and awards from the American Society of Hematology, the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Wellcome Fund, and the Leukemia and Lymphoma Society. He has served on the board of scientific counselors for the National Cancer Institute; the board of external experts for the National Heart, Lung and Blood Institute; the board of directors of the International Society for Stem Cell Research; and is an affiliate member of the Broad Institute of Harvard and MIT. He also serves on multiple editorial boards, scientific advisory boards, and corporate boards, the latter including Agios and Magenta Therapeutics. He is a scientific founder of Fate Therapeutics, Inc., and Magenta Therapeutics, Inc., and serves as a director on Magenta’s board of directors. David also serves on the board of directors of LifeVault Bio and Clear Creek Bio, Inc.

David is a graduate of Bucknell University (B.A.) and Case Western Reserve University (M.D.) with honorary degrees awarded from Harvard University (A.M.), Bucknell University (Sc.D.), Case Western Reserve University (Sc.D.) and Lund University in Sweden (M.D.). He serves as a Visiting Scholar to Pembroke College, University of Cambridge, U.K.

Akshay joined the Editas Medicine Board of Directors in July 2016. He has served as Alnylam’s President of Research and Development since March 2018. He joined Alnylam in January 2006 as VP, Clinical Research, and since that time has held positions of increasing responsibility including SVP, Clinical Research; EVP, Research and Development; and Chief Medical Officer, before assuming his current role. From December 1998 through 2005, he held various positions in medical research at Biogen.

Akshay received his M.D. from the University of Wales College of Medicine, UK, and his Ph.D. from the University of London, UK, in molecular immunology. He is also a Fellow of the Royal College of Physicians, UK. He serves on the board of directors of Scholar Rock, Inc., and previously served on the board of directors of Visterra, Inc.

Our Scientific Founders

Core Member, Broad Institute of MIT and Harvard; Investigator, McGovern Institute for Brain Research, Massachusetts Institute for Technology; W.M. Keck Career Development Professor, Departments of Brain and Cognitive Sciences and Biological Engineering, Massachusetts Institute of Technology; Robertson Investigator, New York Stem Cell Foundation

Feng joined the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard as a core member in 2011. He is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain’s electrical activity to be controlled with light-sensitive proteins. He is now working to extend this molecular engineering approach to other aspects of brain function, such as gene expression, and to develop new approaches to understanding and eventually treating brain diseases. Feng is a Searle Scholar and has received both a Director’s Transformative Research Award and a Director’s Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics.

Feng holds an AB degree in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.

Professor of Genetics, Health Sciences and Technology, Harvard University and MIT; Director of the HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project, Broad Institute and Wyss Harvard Institute of Biologically Inspired Engineering

George is a leading expert in human genetics and biotechnology. He has served as professor of genetics at Harvard Medical School since 1986 and currently serves as professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT). He is also director of the US Department of Energy Center on Bioenergy at Harvard and MIT and director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. George helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George pioneered genome engineering, systems and synthetic biology, and concepts of molecular multiplexing and tags, and he has a successful track record of developing and transferring new technologies to more than 20 companies. George has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and was honored in The Scientist’s Top 10 Innovations list in 2008.

George holds a Ph.D. in biochemistry and molecular biology from Harvard University and a BA in zoology and chemistry from Duke University.

Keith currently serves as professor of pathology at Harvard Medical School and is associate chief of pathology for research and the Jim and Ann Orr Research Scholar at Massachusetts General Hospital (MGH). He is also a member of the Center for Cancer Research and Center for Computational and Integrative Biology at MGH.

Keith has been a pioneer in the development of important technologies for targeted gene editing and epigenome editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery and Transposagen Biopharmaceuticals.

Keith holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School, and an AB degree in biochemical sciences from Harvard College.

David is an accomplished chemist, biologist, and innovator. He currently serves as professor of chemistry and chemical biology at Harvard University, investigator of the Howard Hughes Medical Institute, and vice-chair of the faculty and core institute member of the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT). His research has advanced the fields of therapeutics discovery, laboratory evolution, macromolecular delivery, and gene editing. David’s insight and breadth led him to be tapped to serve as a JASON, an elite group of scientists who advise the US government on matters of science and technology. He is also the recipient of numerous scientific distinctions, including the American Chemical Society Pure Chemistry and Arthur C. Cope Young Scholar Awards, the GlaxoSmithKline Chemistry Scholar Award, the AstraZeneca Pharmaceuticals Excellence in Chemistry Award, the Searle Scholars Award, the National Science Foundation Faculty Early Career Development Award, the Sloan Foundation Fellowship, the Beckman Foundation Young Investigator Award, the Office of Naval Research Young Investigator Award, and the university-wide Roslyn Abramson Award for undergraduate teaching at Harvard. David was named to the Popular Science “Brilliant 10” for young scientists in the US, as well as to the MIT TR100 for young innovators. In 2016 he was named one of the Top 20 Translational Researchers by Nature Biotechnology. His accomplishments also include groundbreaking research leading to the foundation of Ensemble Therapeutics and Permeon Biologics.

David holds a BA degree in chemistry from Harvard College and a Ph.D. in organic chemistry from the University of California, Berkeley.